A5100364910- CAR-T cell therapy research
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Viral Infectious Diseases and Gene Expression in Insects
- Silicon Carbide Semiconductor Technologies
- Hematopoietic Stem Cell Transplantation
- Virus-based gene therapy research
- Acute Lymphoblastic Leukemia research
- Monoclonal and Polyclonal Antibodies Research
- Advanced battery technologies research
- Supercapacitor Materials and Fabrication
- Nanowire Synthesis and Applications
- Immune Response and Inflammation
- Microbial Natural Products and Biosynthesis
- Fungal Biology and Applications
- Chronic Lymphocytic Leukemia Research
- Restraint-Related Deaths
- Histone Deacetylase Inhibitors Research
- Suicide and Self-Harm Studies
- Advanced Machining and Optimization Techniques
- Child and Adolescent Psychosocial and Emotional Development
- NF-κB Signaling Pathways
- Inflammatory Bowel Disease
Suzhou Guangji Hospital
2023
Soochow University
2016-2023
Shaanxi Provincial People's Hospital
2019-2022
Shanxi Medical University
2019-2022
State Key Laboratory of Oncogene and Related Genes
2018-2022
Renji Hospital
2018-2022
Shanghai Cancer Institute
2018-2022
Beijing Proteome Research Center
2022
Chinese PLA General Hospital
2020-2022
Regend Therapeutics (China)
2022
Cancer immunotherapy has made unprecedented breakthrough in the fields of chimeric antigen receptor-redirected T (CAR T) cell therapy and immune modulation. Combination CAR modification disruption endogenous inhibitory checkpoints on cells represent a promising immunotherapeutic modality for cancer treatment. However, potential treatment hepatocellular carcinoma (HCC) not been explored. In this study, gene expressing programmed death 1 receptor (PD-1) Glypican-3 (GPC3)-targeted...
Adoptive immunotherapy based on chimeric antigen receptor-modified T (CAR-T) cells has been demonstrated as one of the most promising therapeutic strategies in treatment malignancies. However, CAR-T cell therapy shown limited efficacy for solid tumors. This is, part, because tumor heterogeneity and a hostile microenvironment, which could suppress adoptively transferred activity. In this study, we, respectively, engineered human- or murine-derived-armored glypican-3 (GPC3)-specific capable...
Background Increasing infiltration of CD8 + T cells within tumor tissue predicts a better prognosis and is essential for response to checkpoint blocking therapy. Furthermore, current clinical protocols use unfractioned cell populations as the starting point transduction chimeric antigen receptors (CARs)-modified cells, but optimal subtype CAR-modified remains unclear. Thus, accurately identifying group cytotoxic lymphocytes with high antitumor efficacy imperative. Inspired by theory yin...
Elderly patients with relapsed and refractory acute lymphoblastic leukemia (ALL) have poor prognosis. Autologous CD19 chimeric antigen receptor-modified T (CAR-T) cells potentials to cure B cell ALL; however, safety efficacy of allogeneic CAR-T are still undetermined. We treated a 71-year-old female ALL who received co-infusion haplo-identical donor-derived CD19-directed mobilized peripheral blood stem (PBSC) following induction chemotherapy. Undetectable minimal residual disease by flow...
Chimeric antigen receptor (CAR) T cell therapy has shown remarkable success in hematological tumors. However, many challenges remain improving the efficacy of CAR cells solid The epidermal growth factor variant III (EGFRvIII) is only expressed tumors but barely found normal tissues, making it a good target for therapy. It reported that 31–64% glioblastoma (GBM) patients are EGFRvIII positive. Here we report robust antitumor activities targeting EGFRvIII-expressing mouse GBM cells. In vitro...
IL12 is an immune-stimulatory cytokine for key immune cells including T and NK cells. However, systemic administration of has serious side effects that limit its clinical application in patients. Recently, synthetic Notch (synNotch) receptors have been developed induce transcriptional activation deliver therapeutic payloads response to the reorganization specific antigens. NK92 cell a human natural killer (NK) line which as tools adjuvant immunotherapy cancer. Here, we explored possibility...
Cancer stem cells (CSCs) are characterized by self-renewal and unlimited proliferation, providing a basis for tumor occurrence, metastasis, recurrence. Because CSCs highly resistant to conventional chemotherapy radiotherapy, various immunotherapies, particularly chimeric antigen receptor T cell (CAR-T) therapy dendritic (DC)-based vaccine therapy, currently being developed. Accordingly, in this study, we evaluated programmed death ligand-1 (PD-L1) expression colorectal (CCSCs) non-CCSCs...
Chimeric antigen receptor (CAR) T cells targeting glypican-3 (GPC3) demonstrated early signs of therapeutic efficacy to hepatocellular carcinoma patients with a risk cytokine release syndrome (CRS). Several adoptive cell therapies (ACTs) using the natural (TCR) signaling induced more efficient antitumor function and reduced production relative CARs in solid tumors. To improve safety GPC3-targeted ACTs, were modified anti-GPC3 single-chain fragment variable(sFv) linked CD3ε, which could be...
Abstract Mucin1 (MUC1) proteins represent a family of high molecular weight trans-membrane glycoproteins that protect epithelial cells and mediate signal transduction by communication with extracellular stimuli. On the other hand, MUC1 has been observed to be overexpressed glycosylated in adenocarcinoma, making it an ideal target for cancer treatment. based antibody specific chimeric antigen receptors (CARs) modified T/NK exhibit strong antibody-dependent or direct-cell cytotoxicity positive...
Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype also frequently expresses Chimeric antigen receptor (CAR) technology a major breakthrough for cancer treatment, the recent approval CD19-directed CAR (CD19CAR) treating B-cell malignancies. However, little information exists on using CD19CAR other positive neoplasms such as AML. Our findings indicate...
TRIP6 is a zyxin family member that serves as an adaptor protein to regulate diverse biological processes. In prior reports, was shown play role in regulating inflammation. However, its vivo roles and mechanistic importance colitis remain largely elusive. Herein, we therefore employed TRIP6-deficient (TRIP6-/-) mice order explore the of dextran sodium sulfate (DSS)-induced model murine colitis.Wild-type (TRIP6+/+) developed more severe following DSS-mediated disease induction relative...
Non-suicidal self-injury (NSSI) is a common feature among adolescents with mood disorders. Although childhood maltreatment has shown to be associated non-suicidal (NSSI), previous studies have yielded mixed results in terms of different subtypes and only few investigated the effects gender. The present cross-sectional study types on NSSI, as well role gender these effects.In this study, total 142 Chinese adolescent inpatients disorders (37 males 105 females) were consecutively recruited...
Autologous CD19-targeted chimeric antigen receptor-modified T cells (CD19-CART) remarkably improved the outcome of patients with advanced B-cell acute lymphoblastic leukemia (B-ALL). However, application and outcomes allogeneic CART is still uncertain. Two B-ALL were enrolled to receive a co-infusion high-dose human leukocyte antigen-haploidentical donor granulocyte colony-stimulating factor mobilized peripheral blood mononuclear (GPBMCs; 21.01–25.34 × 10 8 /kg) same donor-derived...
In order to examine the role of peripheral blood lymphocyte subsets on diagnosis, treatment and prognosis hemophagocytic lymphohistiocytosis (HLH), 30 affected children during acute period disease healthy within same age range were selected test their using flow cytometry compare these subsets. At time, 20 with complete remission from HLH compared those 10 cases who succumbed disease. The proportion CD3+ CD8+ T cells increased in period. Additionally, CD4+ CD3-CDl6+CD56+ natural killer (NK)...
Abstract Richter syndrome (RS) indicates the transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma (mostly DLBCL). is a rare complication with clinical course, bearing unfavorable prognosis. Currently, there no effective treatment for it. As novel cellular‐based immune therapy, chimeric antigen receptor‐modified T (CART) cells gradually used in treating hematological malignancies, especially CD19 + B‐cell malignancy. Therefore, CD19‐directed (CART‐19) promising to...
To explore the immune cell therapy for T lymphoma, we developed CD4-specific chimeric antigen receptor- (CAR-) engineered cells (CD4CART), and cytotoxic effects of CD4CART were determined in vitro vivo.
Abstract Richter syndrome (RS) indicates the transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma (mostly DLBCL). RS is a rare complication with unfavorable clinical outcome. There no effective treatment for it currently. As new type cell-based immune therapy, chimeric antigen receptor modified T (CAR-T) cell now widely used in treating hematological malignancies, especially CD19+ B malignancy. Therefore, CD19-directed cells (CART-19) worthwhile to be developed as...
Abstract Post-remission strategies for patients with acute lymphoblastic leukemia (ALL) are limited to the multiagent chemotherapy and allogeneic stem cell transplant (allo-SCT), cellular therapies seldom involved. Although combined mismatched granulocyte colony-stimulating factor mobilized peripheral blood mononuclear infusion (microtransplant, MST) has been studied in myeloid leukemia, its efficacy ALL is still undetermined. We enrolled 48 receiving hyper-CVAD-based MST between July 1,...
Germinal center (GC) is the vital locus for evolution of naïve B cells into memory and plasma cells, but also a hotbed proliferation malignant cells. We hypothesized that may locally or globally impact GCs to produce peripheral cell receptor immune repertoire (BCR IR) with reduced clonal diversity. In this study, we first validated our hypothesis in novel human in-vitro GC (hiGC) model. The addition diffuse large lymphoma (DLBCL) hiGC culture attenuated rate diversity growth. For clinical...